Get started
Author

Allison Komirenko

Observed names: A.S., Komirenko, Allison S Komirenko, Allison S. Komirenko, Komirenko AS, Komirenko, Allison, Komirenko, Allison S.
Observed institutions: University of California, Los Angeles, The Lundquist Institute, University of California, San Francisco, Justus-Liebig-Universität Gießen, Ascendis Pharma (Denmark), Harbor–UCLA Medical Center, Achaogen (United States), Vanderbilt University Medical Center
ORCID: 0000-0001-8844-2804
Observed ORCID: 0000-0001-8844-2804
OpenAlex ID: A5031197924
Once-Daily Plazomicin for Complicated Urinary Tract Infections
2019 · Florian M.E. Wagenlehner, Daniel J. Cloutier, et al. · New England Journal of Medicine · 218
Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
2022 · Aristides K Maniatis, Samuel J Casella, et al. · The Journal of Clinical Endocrinology & Metabolism · 31
Activation of the Keap1/Nrf2 stress response pathway in autophagic vacuolar myopathies
2016 · Steve Duleh, Xianhong Wang, et al. · Acta Neuropathologica Communications · 30
PDF
Plazomicin Vs. Meropenem for Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): Diagnosis-specific Results From the Phase 3 EPIC Study
2017 · Daniel J Cloutier, Allison S Komirenko, et al. · Open Forum Infectious Diseases · 23
Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial
2022 · Aristides K. Maniatis, Ulhas Nadgir, et al. · Hormone Research in Paediatrics · 21
A Phase 1 Study To Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function
2018 · Allison S. Komirenko, Valerie Riddle, et al. · Antimicrobial Agents and Chemotherapy · 12
Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results
2025 · Aristides K. Maniatis, Paul S. Thornton, et al. · Hormone Research in Paediatrics · 10
Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection
2019 · Tomefa E. Asempa, Joseph L. Kuti, et al. · Antimicrobial Agents and Chemotherapy · 7
A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales
2019 · Tomefa E. Asempa, Joseph L. Kuti, et al. · Clinical Therapeutics · 7
No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects
2019 · Taylor Choi, Allison S. Komirenko, et al. · Clinical Pharmacology in Drug Development · 7
Prevalence, Treatment Patterns, and Characteristics of US Adults with Confirmed or at Risk for Growth Hormone Deficiency
2025 · Andrew R. Hoffman, Subhara Raveendran, et al. · Advances in Therapy · 6
PDF
Economic burden of growth hormone deficiency among adults who are at risk for and who have confirmed growth hormone deficiency using US real-world data
2025 · Andrew R. Hoffman, Subhara Raveendran, et al. · Journal of Medical Economics · 3
Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
2021 · Aristides K Maniatis, Samuel J Casella, et al. · Journal of the Endocrine Society · 3
PDF
12542 Results Of The Foresight Trial Support The Efficacy And Safety Of Once-weekly Lonapegsomatropin In Adults With Growth Hormone Deficiency (ghd)
2024 · Beverly Mk Biller, Aleksandra Gilis-Januszewska, et al. · Journal of the Endocrine Society · 2
PDF
Improved Outcomes at Late Follow-up (LFU) with Plazomicin Compared with Meropenem in Patients with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) in the EPIC Study
2017 · Yoav Golan, Daniel J Cloutier, et al. · Open Forum Infectious Diseases · 2
PDF
Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial
2026 · Ciara M McDonnell, Melita Irving, et al. · European Journal of Endocrinology · 1
PMON64 Economic Burden of Growth Hormone Deficiency in a US Adult Population
2022 · Alden Smith, Janna Manjelievskaia, et al. · Journal of the Endocrine Society · 1
PDF
Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
2021 · Maria Fleseriu, Jens Otto Jorgensen, et al. · Journal of the Endocrine Society · 1
124. Microbiological Outcomes With Plazomicin (PLZ) Versus Meropenem (MEM) in Patients With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in the EPIC Study
2018 · Tiffany R Keepers, Deborah S Cebrik, et al. · Open Forum Infectious Diseases · 1
Long-term Safety and Efficacy of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: Results From a 52-Week Open-Label Extension Trial
2026 · Beverly M.K. Biller, Aleksandra Gilis-Januszewska, et al. · Endocrine Practice
Immunogenicity Profile of Lonapegsomatropin During Long-Term Treatment in Children With Growth Hormone Deficiency
2026 · Per Holse Mygind, Amiee Weiser, et al. · The AAPS Journal
PDF
O04: Growth outcomes and safety of navepegritide in children with achondroplasia: Results of the ApproaCH trial open label extension
2026 · Ravi Savarirayan, Carlos Bacino, et al. · Genetics in Medicine Open
PDF
Safety and effectiveness of lonapegsomatropin in children with growth hormone deficiency: a plain language summary
2025 · Aristides K. Maniatis, Kylene Cardon, et al. · Future Rare Diseases
PDF
Effects of navepegritide on growth in children with achondroplasia: 52-week results from the approach clinical trial
2025 · Hanne Hove, Ciara McDonnell, et al. · Endocrine Abstracts
Results of the foresiGHt trial support the efficacy and safety of once-weekly lonapegsomatropin in adults with growth hormone deficiency (GHD)
2025 · Aleksandra Gilis-Januszewska, Beverly M.K. Biller, et al. · Endocrine Abstracts
Works count: 44
Citation count: 386
H-index: 7
I10-index: 7
Year
Topic
Type